Details for New Drug Application (NDA): 050341
✉ Email this page to a colleague
NDA 050341 describes FUNGIZONE, which is a drug marketed by Apothecon and Bristol Myers Squibb and is included in five NDAs. Additional details are available on the FUNGIZONE profile page.
The generic ingredient in FUNGIZONE is amphotericin b. There are fifteen drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the amphotericin b profile page.
The generic ingredient in FUNGIZONE is amphotericin b. There are fifteen drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the amphotericin b profile page.
Summary for 050341
| Tradename: | FUNGIZONE |
| Applicant: | Bristol Myers Squibb |
| Ingredient: | amphotericin b |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 050341
Profile for product number 003
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | SUSPENSION;ORAL | Strength | 100MG/ML | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
